<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154626">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01791491</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-144</org_study_id>
    <secondary_id>2011-005257-31</secondary_id>
    <nct_id>NCT01791491</nct_id>
  </id_info>
  <brief_title>Phase II Pharmacokinetics, Efficacy, and Safety of Belatacept in Pediatric Renal Transplant Recipients</brief_title>
  <official_title>A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects With a Stable Renal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics (PK) efficacy and safety of
      Belatacept in stable pediatric renal transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>8 time points following SD administration up to Day 57</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>8 time points following SD administration up to Day 57</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]</measure>
    <time_frame>8 time points following SD administration up to Day 57</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>8 time points following SD administration up to Day 57</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (T-HALF)</measure>
    <time_frame>8 time points following SD administration up to Day 57</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CLT)</measure>
    <time_frame>8 time points following SD administration up to Day 57</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution at steady-state (Vss)</measure>
    <time_frame>8 time points following SD administration up to Day 57</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state trough concentration (Cmin)</measure>
    <time_frame>25 time points following MD administration up to Week 24 of Follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be measured by proportion of subjects reporting Adverse Event (AE), Serious AE, and AE leading to early discontinuation</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers against Belatacept</measure>
    <time_frame>Day 1, 15, 29, and 57 in SD phase; Day 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365, every 6 months up to 3 Years , Weeks  8,12, 24 follow up in MD phase</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD86 receptor occupancy in Blood samples</measure>
    <time_frame>Day1, 29 and 57 in SD phase; Day1, 29, 57, Month 6, and 12 in MD phase</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by estimated glomerular filtration rate (eGFR) [calculated by updated Schwartz formula]</measure>
    <time_frame>3, 6, 12, 24, and 36 months in MD and Long Term Extension (LTE) phases</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by change in eGFR</measure>
    <time_frame>Day 1, Month 12, 24 and 36 in MD and LTE phases</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by incidence and severity of AR</measure>
    <time_frame>6, 12, 24, and 36 months  in MD and LTE phases</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by incidence of death and graft loss</measure>
    <time_frame>6, 12, 24, and 36 months in MD and LTE phases</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>Arm 1-SD: Belatacept + Tacrolimus + CsA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Belatacept 7.5-12.5 mg/kg intravenous (IV) infusion once in 2 months
Tacrolimus capsule by mouth as per label for 2 months
Cyclosporine (CsA) capsule or liquid by mouth as per label for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2-MD: Belatacept + CsA or Tacrolimus + CsA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Belatacept 7.5-12.5 mg/kg intravenous (IV) infusion every 2 weeks until week 8 then every 4 weeks for 3 years
Tacrolimus capsule by mouth as per label for 3 years
OR
Cyclosporine (CsA) capsule or liquid by mouth as per label for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <arm_group_label>Arm 1-SD: Belatacept + Tacrolimus + CsA</arm_group_label>
    <arm_group_label>Arm 2-MD: Belatacept + CsA or Tacrolimus + CsA</arm_group_label>
    <other_name>BMS-224818</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>Arm 1-SD: Belatacept + Tacrolimus + CsA</arm_group_label>
    <arm_group_label>Arm 2-MD: Belatacept + CsA or Tacrolimus + CsA</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA</intervention_name>
    <arm_group_label>Arm 1-SD: Belatacept + Tacrolimus + CsA</arm_group_label>
    <arm_group_label>Arm 2-MD: Belatacept + CsA or Tacrolimus + CsA</arm_group_label>
    <other_name>Neoral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  6-17 years old

          -  Recipients of a renal allograft from a living donor or a deceased donor at least 6
             months prior to enrollment

          -  Subject must be receiving a calcineurin inhibitor (CNI)-based [cyclosporine (CsA)
             [any formulation] or Tacrolimus (TAC)] immunosuppressive regimen

          -  Subject must be receiving adjunctive background maintenance immunosuppression with
             mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium
             (EC-MPS)/mycophenolic acid (MPA)

          -  Subjects must be receiving a stable dose of corticosteroids

          -  Subject must have stable estimated glomerular filtration rate (GFR) ≥45 mL/min/1.73m2
             (updated Schwartz formula)

        Exclusion Criteria:

          -  Epstein-Barr virus (EBV) serostatus negative or unknown at time of transplant and
             screening

          -  History of any treated or biopsy proven acute rejection (BPAR) within 3 months prior
             to randomization

          -  Subjects who have experienced more than 1 episode of acute rejection (AR) of the
             current allograft or any antibody-mediated AR

          -  Significant proteinuria

          -  Active infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Of Alabama At Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Feig, Site 0004</last_name>
      <phone>205-638-2792</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Of La</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Lemley, Site 0001</last_name>
      <phone>323-361-7299</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Ettenger, Site 0002</last_name>
      <phone>310-206-8415</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Grimm, Site 0006</last_name>
      <phone>650-725-5295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens National Medical Center</name>
      <address>
        <city>District of Columbia</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asha Moudgil, Site 0007</last_name>
      <phone>202-476-2245</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry Warshaw, Site 0012</last_name>
      <phone>404-712-9923</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Harmon, Site 0008</last_name>
      <phone>617-355-8314</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Dharnidharka, Site 0003</last_name>
      <phone>314-747-1349</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children'S Hospital Of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Amaral, Site 0009</last_name>
      <phone>267-425-3932</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>January 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
